Online interest in calcitonin gene‐related peptide‐therapies: An infodemiology study using Google trends
Headache: The Journal of Head and Face Pain · 2026
DOI: 10.1111/head.70136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2026. Verfasst von Bradley Ong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide Receptor Antagonists, Calcitonin Gene-Related Peptide, Migraine Disorders, Search Engine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To evaluate changes in public interest in calcitonin gene‐related peptide therapies associated with major product lifecycle milestones using online search data from the United States and Europe.
Background
Calcitonin gene‐related peptide therapies have transformed migraine treatment, but the impact of key product lifecycle milestones on public awareness remains unclear. As patients increasingly turn to online platforms for health information, events such as trial publications, regulatory approvals, commercial launches, and advertising campaigns may drive search activity and signal broader awareness.
Methods
We conducted a retrospective ecological infodemiology study using a quasi‐experimental interrupted time‐series design with monthly Google Trends data (January 2017–July 2025). Search volume index (0–100 scale) was assessed for seven CGRP‐therapies. Milestone events (trial publications, regulatory approvals, commercial launches, and media exposure) were defined a priori as potential drivers of digital impact. We evaluated immediate and sustained changes in search interest following major milestones over time. The primary analysis included all therapies in the United States; secondary analyses evaluated erenumab across five European countries (Germany, France, Italy, Spain, and United Kingdom).
Results
In the United States, commercial launch was associated with significant immediate increases in search interest for erenumab (β = 102.54; 95% confidence interval [CI], 17.05–188.02, p = 0.021) and galcanezumab (brand search term) (β = 42.36; 95% CI, 15.80–68.91, p = 0.002). Sustained post‐launch growth was observed for fremanezumab (brand search term) (β = +0.50/month; 95% CI, 0.27–0.73, p < 0.001), eptinezumab (β = +0.45/month; 95% CI, 0.26–0.64, p < 0.001), rimegepant (brand search term) (β = +0.97/month; 95% CI, 0.47–1.47, p < 0.001), atogepant (brand search term) (β = +1.28/month; 95% CI, 0.70–1.85, p < 0.001), and ubrogepant (brand search term) (β = +0.59/month; 95% CI, 0.42–0.77, p < 0.001). Media exposure was associated with significant immediate increases for erenumab (β = 94.33; 95% CI, 11.17–177.50, p = 0.029) and ubrogepant (β = 29.77; 95% CI, 11.12–48.41, p = 0.003). Regulatory approvals and trial publications were not consistently associated with significant changes in search interest. In Europe, commercial launch was associated with significant immediate increases for erenumab (generic search term) in Italy (β = 126.82; 95% CI, 62.12–191.52, p < 0.001), erenumab (brand search term) in Italy (β = 142.98; 95% CI, 23.88–262.08, p = 0.021) and the United Kingdom (β = 69.44; 95% CI, 6.71–132.16, p = 0.033). Post‐launch trends were generally negative across countries, indicating gradual declines after initial spikes.
Conclusions
Commercial launch was the most consistent driver of public search interest in CGRP‐targeting therapies. Media exposure produced additional increases in selected cases, whereas regulatory approvals and clinical trial publications had limited measurable impact. These findings underscore the dominant role of commercial and consumer‐facing communication in shaping public awareness of new migraine treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Sleep Disorders Center, Neurological Institute, Cleveland, Ohio, USA.
- Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
- Center for Outcomes Research & Evaluation, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Ohio University Heritage College of Osteopathic Medicine, Cleveland, Ohio, USA.
- Yale University School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Bradley Ong, Jad El Ahdab
Zitieren
APA
Ong, B., Ahdab, J. E., Thompson, N., Bhagat, M., Ney, J., & Weathers, A. L. (2026). Online interest in calcitonin gene‐related peptide‐therapies: An infodemiology study using Google trends. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.70136
Vancouver
Ong B, Ahdab JE, Thompson N, Bhagat M, Ney J, Weathers AL. Online interest in calcitonin gene‐related peptide‐therapies: An infodemiology study using Google trends. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70136
BibTeX
@article{Ong2026,
author = {Ong, Bradley and Ahdab, Jad El and Thompson, Nicolas and Bhagat, Maithili and Ney, John and Weathers, Allison L},
title = {Online interest in calcitonin gene‐related peptide‐therapies: An infodemiology study using Google trends},
journal = {Headache: The Journal of Head and Face Pain},
year = {2026},
doi = {10.1111/head.70136}
}
EUVIMED